Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H27N9O7S2 |
| Molecular Weight | 593.636 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CN3N=NC(C)=N3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)C4=CSC(N)=N4
InChI
InChIKey=UIYAXIPXULMHAI-JLGRZTKVSA-N
InChI=1S/C22H27N9O7S2/c1-10-26-29-30(27-10)6-11-7-39-18-14(25-16(32)13(28-36-5)12-8-40-21(23)24-12)17(33)31(18)15(11)19(34)37-9-38-20(35)22(2,3)4/h8,14,18H,6-7,9H2,1-5H3,(H2,23,24)(H,25,32)/b28-13-/t14-,18-/m1/s1
| Molecular Formula | C22H27N9O7S2 |
| Molecular Weight | 593.636 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.e-search.ne.jp/~jpr/PDF/TOYAMA05.PDF
Sources: http://www.e-search.ne.jp/~jpr/PDF/TOYAMA05.PDF
Cefteram is a semisynthetic cephalosporin formulated for oral administration as the prodrug ester, cefteram pivoxil. The mechanism of action of cefteram is inhibition of bacterial cell wall synthesis. Cefteram exerts its bactericidal activity by strongly binding to penicillin-binding protein (PBP) 3, 1A, and 1Bs. The drug is available in Japan and is used for the treatment of bacterial infections.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1813 Sources: http://www.e-search.ne.jp/~jpr/PDF/TOYAMA05.PDF |
|||
Target ID: CHEMBL1814 Sources: http://www.e-search.ne.jp/~jpr/PDF/TOYAMA05.PDF |
|||
Target ID: CHEMBL4269 Sources: http://www.e-search.ne.jp/~jpr/PDF/TOYAMA05.PDF |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | TOMIRON Approved UseTo treat pharyngitis/laryngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, and secondary infections in chronic respiratory lesion; cystitis, pyelonephritis and urethritis; bartholinitis, intrauterine infection and uterine adnexitis; otitis media and sinusitis; periodontitis, pericoronitis and gnathitis |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.32 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18498914/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFTERAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.22 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18498914/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFTERAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.65 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20166432/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFTERAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
1.73 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20166432/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFTERAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.79 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18498914/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFTERAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18498914/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFTERAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.89 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20166432/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFTERAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
4.76 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20166432/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFTERAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.16 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18498914/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFTERAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18498914/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFTERAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.32 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20166432/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFTERAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
1.33 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20166432/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFTERAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests. | 1987-09 |
|
| In vitro activity of Ro 19-5247 (T-2525) and interpretive criteria for disk diffusion susceptibility testing. | 1987-07 |
|
| In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. | 1987-03 |
|
| In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074). | 1986-09 |
|
| In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites. | 1986-06 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.e-search.ne.jp/~jpr/PDF/TOYAMA05.PDF
The usual adult dosage for oral use is 150 − 600 mg (potency) of cefteram pivoxil daily in 3 divided doses after meals.
Route of Administration:
Oral
The activity of cefteram was compared with that of other P-lactams against a total of 491 bacterial strains. The drug was highly active (MIC for 90% of the strains tested [MIC90] < 2 ug/ml) against the majority of the members of the family Enterobacteriaceae, Haemophilus influenzae, Neisseria spp., and Streptococcuspneumoniae, being at least 16-fold more active than cephalexin and 8-fold more active than cefuroxime. There was no activity against Pseudomonas aeruginosa, Enterobacter sp., and Citrobacter sp. Staphylococcus aureus was moderately susceptible to cefteram (MIC90, 8 ug/ml).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:32:27 GMT 2025
by
admin
on
Mon Mar 31 21:32:27 GMT 2025
|
| Record UNII |
0OD86RT58C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C357
Created by
admin on Mon Mar 31 21:32:27 GMT 2025 , Edited by admin on Mon Mar 31 21:32:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2105953
Created by
admin on Mon Mar 31 21:32:27 GMT 2025 , Edited by admin on Mon Mar 31 21:32:27 GMT 2025
|
PRIMARY | |||
|
C046817
Created by
admin on Mon Mar 31 21:32:27 GMT 2025 , Edited by admin on Mon Mar 31 21:32:27 GMT 2025
|
PRIMARY | |||
|
C98230
Created by
admin on Mon Mar 31 21:32:27 GMT 2025 , Edited by admin on Mon Mar 31 21:32:27 GMT 2025
|
PRIMARY | |||
|
SUB01135MIG
Created by
admin on Mon Mar 31 21:32:27 GMT 2025 , Edited by admin on Mon Mar 31 21:32:27 GMT 2025
|
PRIMARY | |||
|
560
Created by
admin on Mon Mar 31 21:32:27 GMT 2025 , Edited by admin on Mon Mar 31 21:32:27 GMT 2025
|
PRIMARY | |||
|
82547-81-7
Created by
admin on Mon Mar 31 21:32:27 GMT 2025 , Edited by admin on Mon Mar 31 21:32:27 GMT 2025
|
PRIMARY | |||
|
DTXSID401316612
Created by
admin on Mon Mar 31 21:32:27 GMT 2025 , Edited by admin on Mon Mar 31 21:32:27 GMT 2025
|
PRIMARY | |||
|
100000084702
Created by
admin on Mon Mar 31 21:32:27 GMT 2025 , Edited by admin on Mon Mar 31 21:32:27 GMT 2025
|
PRIMARY | |||
|
m3219
Created by
admin on Mon Mar 31 21:32:27 GMT 2025 , Edited by admin on Mon Mar 31 21:32:27 GMT 2025
|
PRIMARY | Merck Index | ||
|
0OD86RT58C
Created by
admin on Mon Mar 31 21:32:27 GMT 2025 , Edited by admin on Mon Mar 31 21:32:27 GMT 2025
|
PRIMARY | |||
|
5362114
Created by
admin on Mon Mar 31 21:32:27 GMT 2025 , Edited by admin on Mon Mar 31 21:32:27 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
||
|
METABOLITE -> PARENT |
Does not undergo extensive metabolism. Excretion in urine. Can lead to depletion of carnitine.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|